Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase III trials of ruxolitinib in vitiligo meet endpoints

May 17, 2021

Dosing begins in phase II trial of CGB-400 for rosacea

May 14, 2021

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

May 12, 2021

GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis

May 11, 2021

Topline phase IIa data reported on FOL-005 for alopecia

May 7, 2021

Aslan Pharmaceuticals presents phase I data for the IL13RA1 inhibitor ASLAN-004

May 7, 2021

BioCryst Pharmaceuticals patent details complement factor D inhibitors

May 6, 2021

BioCryst Pharmaceuticals presents complement factor D inhibitors

May 5, 2021

Promising safety data from first dose cohort of phase I study evaluating DSG3-CAART

May 4, 2021

FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis

May 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...